Scarica l'app Stockscreener
14.71
0.41%
-0.06
Dopo l'orario di chiusura:
14.71
Precedente Chiudi:
$14.77
Aprire:
$14.63
Volume 24 ore:
2.08M
Relative Volume:
0.36
Capitalizzazione di mercato:
$1.39B
Reddito:
-
Utile/perdita netta:
$-313.94M
Rapporto P/E:
-4.1957
EPS:
-3.506
Flusso di cassa netto:
$-284.57M
1 W Prestazione:
+0.55%
1M Prestazione:
+51.65%
6M Prestazione:
+75.96%
1 anno Prestazione:
+159.44%
Intervallo 1D:
$14.11
$15.04
Intervallo di 1 settimana:
$13.81
$15.64
Portata 52W:
$1.50
$15.71
Replimune Group Inc Stock (REPL) Company Profile
Nome
Replimune Group Inc
Settore
Industria
Telefono
(781) 222-9600
Indirizzo
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
14.71 | 1.32B | 0 | -313.94M | -284.57M | -3.506 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | Downgrade | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2026-04-13 | Downgrade | Jefferies | Buy → Hold |
| 2026-04-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | Downgrade | Wedbush | Outperform → Neutral |
| 2026-04-10 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-09-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-06-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-04-17 | Ripresa | Piper Sandler | Overweight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-17 | Iniziato | BTIG Research | Buy |
| 2020-11-02 | Iniziato | Jefferies | Buy |
| 2020-10-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-09-04 | Iniziato | ROTH Capital | Buy |
| 2019-07-23 | Iniziato | Chardan Capital Markets | Buy |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-25 | Iniziato | Wedbush | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Iniziato | JP Morgan | Overweight |
| 2018-08-14 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Replimune Group Inc Borsa (REPL) Ultime notizie
Replimune Group Lawsuit Focuses on FDA Disclosure Issues and Sharp REPL Stock Drop - TipRanks
Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action - PR Newswire
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
DEADLINE ALERT for BZAI, BABA, ALAR, and REPL: The Law - GlobeNewswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - YCharts
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today? - Stocktwits
Replimune (REPL) Results at a Glance: Profit Per Share Falls Below Its Benchmark; Market Response: Shares Move Lower 3.31% in the Available RecordFinancial Summary - vinanet.vn
REPL UPCOMING DEADLINE: SueWallSt Alerts Replimune Group, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, - GlobeNewswire
Replimune (REPL) Earnings Update: The Bottom-Line Figure Trails Its Comparison in the Latest Reading; Market Reaction: The Stock Ends Down 3.88% in the Latest ReadingDownward Estimate Revision - vinanet.vn
Replimune CFO Emily Hill sells $132,175 in stock for tax obligations - Investing.com Canada
Replimune Group (NASDAQ:REPL) CFO Sells $132,175.68 in Stock - MarketBeat
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders - GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Press Release: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Replimune faces securities lawsuit over alleged FDA disclosure omissions on RP1 drug approval risks. - Pluang
REPL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Replimune Soars Over 120% as FDA Panel Backs Melanoma Therapy Ahead of August Decision - finance.biggo.com
Trump picks White House adviser Heidi Overton to run FDA, source says - marketscreener.com
NASDAQ: REPL Investor Alert: Lawsuit against Replimune Group, Inc. seeks to recover Investor losses - openPR.com
Replimune Group (NASDAQ:REPL) Shares Up 5.2%What's Next? - MarketBeat
Shareholders of Replimune Group urged to join c... - Pluang
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. LawsuitREPL - PR Newswire
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
REPL Ignites On Doctor Fury Against FDA’s Melanoma Drug Snub — Health Sec Steps Back - Stocktwits
Quantinno Capital Management LP Increases Stock Position in Replimune Group, Inc. $REPL - MarketBeat
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome - Stocktwits
Did You Lose Money Investing in Replimune Group, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About their Rights Against REPL - The Globe and Mail
REPL DEADLINE: Levi & Korsinsky Reminds Replimune Group, - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2026-08-16 | REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REPL | Press Release - Stockhouse
Replimune Raises $150 Million To Fund TUDRIQEV Launch And Confirmatory Trial - Pulse 2.0
REPL SWOT Analysis: FDA Approval of TUDRIQEV Marks a Turning Point - GuruFocus
Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line - Stocktwits
Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results - MarketBeat
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Form 8K Replimune Group Inc For: 7 August By Investing.com - Investing.com Nigeria
Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed - TradingView
Replimune (NASDAQ: REPL) secures FDA accelerated approval and raises $141M - Stock Titan
Replimune Group (REPL): Ridgeback Capital now reports 3.5% ownership stake - Stock Titan
Why Is Replimune (NASDAQ:REPL) Drawing Attention After Its Oncology Approval? - Kalkine Media
Replimune Group Releases Q1 2027 Financial Results - AlphaStreet
2026-08-14 | REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REPL | Press Release - Stockhouse
Replimune Group stock may move 5.6% on earnings release By Investing.com - Investing.com Canada
REPL Shareholder Alert: Replimune Group, Inc. Securities - GlobeNewswire
Replimune Group stock may move 5.6% on earnings release - Investing.com
Replimune Q1 EPS $(0.72) beats estimate; FDA approves TUDRIQEV - scanx.trade
Replimune Group Inc Azioni (REPL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Replimune Group Inc Azioni (REPL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Patel Sushil | Chief Executive Officer |
Aug 10 '26 |
Sale |
12.97 |
39,341 |
510,253 |
708,151 |
| Hill Emily Luisa | Chief Financial Officer |
Aug 10 '26 |
Sale |
12.97 |
11,448 |
148,481 |
225,108 |
| Xynos Konstantinos | Chief Medical Officer |
Aug 10 '26 |
Sale |
12.97 |
11,447 |
148,468 |
224,215 |
| Schwendenman Andrew | Chief Accounting Officer |
Aug 10 '26 |
Sale |
12.97 |
7,632 |
98,987 |
99,425 |
| Sarchi Christopher | Chief Commercial Officer |
Jun 01 '26 |
Sale |
9.24 |
12,000 |
110,880 |
180,962 |
| Xynos Konstantinos | Chief Medical Officer |
May 18 '26 |
Sale |
5.08 |
14,023 |
71,237 |
235,662 |
| Schwendenman Andrew | Chief Accounting Officer |
May 18 '26 |
Sale |
5.08 |
7,894 |
40,102 |
107,057 |
| Sarchi Christopher | Chief Commercial Officer |
May 18 '26 |
Sale |
5.08 |
8,626 |
43,820 |
192,962 |
| Astley-Sparke Philip | Director |
May 18 '26 |
Sale |
5.08 |
17,657 |
89,698 |
1,412,414 |
| Patel Sushil | Chief Executive Officer |
May 18 '26 |
Sale |
5.08 |
37,324 |
189,606 |
747,492 |
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):